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Abstract 35 
Background 36 
Some previous studies suggest a long term association between clarithromycin use 37 
and cardiovascular events. This study investigates this association for clarithromycin 38 
given as part of Helicobacter pylori treatment (HPT). 39 
Methods 40 
Our source population was the Clinical Practice Research Datalink (CPRD), a UK 41 
primary care database. We conducted a self-controlled case series (SCCS), a case-42 
time-control study (CTC) and a propensity score adjusted cohort study comparing the 43 
rate of cardiovascular events in the 3 years after exposure to HPT containing 44 
clarithromycin with exposure to clarithromycin free HPT.  45 
Outcomes were first incident myocardial infarction, arrhythmia and stroke. For the 46 
cohort analysis we included secondary outcomes all-cause and cardiovascular 47 
mortality.  48 
Results 49 
28,552 patients were included in the cohort. The incidence rate ratio of first MI within 50 
a year of exposure to HPT containing clarithromycin was 1.07 (95% CI: 0.85-1.34, 51 
p=0.58) and within 90 days was 1.43 (95% CI: 0.99-2.09 p=0.057) in the SCCS 52 
analysis. CTC and cohort results were consistent with these findings. 53 
Conclusions 54 
There was some evidence for a short term association for first MI but none for a long 55 
term association for any outcome.   56 
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What is known about this subject 57 
 Previous epidemiological studies suggest that clarithromycin is associated 58 
with an increased risk of cardiovascular events at least a year after exposure 59 
 A recent study in a Hong Kong population suggests that there is no long term 60 
risk, only a short term risk associated with currently taking the drug 61 
What this study adds 62 
 This study corroborates the findings of the Hong Kong study in a larger UK 63 
population that has been well validated for cardiovascular outcomes 64 
 Clarithromycin is not associated with a long term increased risk of 65 
cardiovascular events 66 
 There is some evidence for an increased short term risk 67 
Abbreviations 68 
BMI Body Mass Index 69 
BNF British National Formulary 70 
CPRD Clinical Practice Research Datalink 71 
CTC Case-Time-Control study 72 
GP General Practitioner 73 
HES Hospital Episodes Statistics 74 
MI Myocardial Infarction 75 
ONS Office of National Statistics 76 
RCT Randomised Controlled Trial 77 
SCCS Self-Controlled Case Series 78 
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HPT Helicobacter pylori treatment 79 
CHPT Clarithromycin containing HPT 80 
NHPT Clarithromycin free HPT  81 
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Background 82 
Clarithromycin is a very commonly prescribed antibiotic in both primary and 83 
secondary care settings. As well as having specific indications, it is one of the most 84 
commonly prescribed alternatives for patients allergic to penicillin. The summary of 85 
product characteristics states that clarithromycin, along with other macrolides, can 86 
cause QT prolongation and thereby increase the short term risk of cardiac 87 
arrhythmias. However two recent papers have suggested an association between 88 
clarithromycin exposure and a broad range of subsequent cardiovascular events that 89 
extends for at least one year after taking the course of medication[1,2]. This is 90 
incompatible with temporary QT prolongation being the underlying mechanism and if 91 
this association were causal, it could have profound implications for clarithromycin 92 
prescribing.  93 
 94 
It is possible that in previous studies people given clarithromycin were generally 95 
frailer than people given other antibiotics despite correction for measured 96 
confounders. This type of indication bias is common in observational studies of drug 97 
effects and can lead to findings of non-causal associations. To avoid this, we have 98 
chosen to restrict our investigation to the association between clarithromycin given as 99 
part of Helicobacter pylori Treatment (HPT) and subsequent cardiovascular events. 100 
The restriction to HPT regimes should reduce confounding by indication, as the 101 
choice of HPT regime is unlikely to be closely linked with a patient’s underlying risk 102 
of cardiovascular outcomes. Furthermore, we employed three study designs with 103 
complementary strengths and weaknesses to further guard against conclusions based 104 
on potentially biased results. A causal association should show a consistent pattern 105 
across study designs whereas discordant findings may suggest important bias. Finally, 106 
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we have completed this study protocol in a Hong Kong population cohort to ensure 107 
generalisability to different ethnicities and to guard against biases derived from a 108 
single health care database.[3] 109 
Methods 110 
Clinical Practice Research Datalink (CPRD) 111 
The CPRD is a large UK primary care electronic healthcare records database widely 112 
validated for epidemiological research [4]. A subset of the CPRD database has been 113 
linked to the Office of National Statistics (ONS) and Hospital Episodes Statistics 114 
(HES) databases which provides cause of death data and hospital discharge 115 
information respectively. We will use the full CPRD database for all outcomes except 116 
for mortality outcomes where we will use this linked subset. 117 
Selection of participants 118 
Patients were selected from the population registered at participating general practices 119 
that were up to research standard before January 2014. All patients exposed to HPT 120 
during the registration period were included. Patients who had either exposure or 121 
outcome recorded during their first year of registration in the database were excluded 122 
from the cohort since records entered close to registration could reflect historic data.  123 
Exposure 124 
Exposure to HPT was determined by prescription for all three components of a triple 125 
therapy regime listed in the British National Formulary (BNF) on the same day. It was 126 
considered very unlikely to receive this particular combination of drugs for any other 127 
indication. We included patients who received courses of treatment lasting between 128 
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one and two weeks duration. Patients who received a prescription for a HPT regime 129 
containing clarithromycin (CHPT) were the exposed group and for the cohort design, 130 
patients who received a prescription for a clarithromycin free HPT regime (NHPT) 131 
were the unexposed comparator group. The comparator group was chosen to 132 
minimise the risk of indication bias as both regimes have the same indication. All 133 
regimes were taken from the BNF and are listed in S1 Appendix. There were 134 
insufficient patients with a specific Read code for H. pylori infection to use these in 135 
our exposure definition. However, we conducted a sensitivity analysis using the 136 
subset of patients who also had a Read code for H. pylori to validate our approach. 137 
Outcomes 138 
First recorded incident diagnosis of MI, arrhythmia and stroke were analysed as 139 
separate outcome measures for all three study designs. These outcomes were selected 140 
as they were components of the composite outcomes reported by Schembri et al[2]. 141 
All subsequent diagnoses of the same event type were excluded to reduce the 142 
possibility of a repeated entry of the same event. The validity of recording of MI in 143 
the CPRD has previously been confirmed by Herrett et al. [5] However, they 144 
described a small delay between MI events coded in CPRD compared with the same 145 
events coded in HES. It is possible that this delay might either reduce the power of 146 
our analysis or result in a delayed association being found. This would particularly 147 
affect the self-controlled case series method and we conducted a sensitivity analysis 148 
using this method in subset of CPRD patients who have linked HES records using 149 
HES MI dates. 150 
 151 
All-cause mortality and cardiovascular mortality were included for the cohort design 152 
only since the self-controlled methods would be biased for this outcome. 153 
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Cardiovascular mortality was obtained from linked ONS data, which was available 154 
from 1st January 1998 to 10th January 2012 for a subset of CPRD. 155 
Propensity Adjusted Cohort Study 156 
Patients entered this study from the day they first received a prescription for any form 157 
of HPT. They were followed up for three years. For all patients in the cohort follow 158 
up was censored at the first date of any of the following: leaving the CPRD; death; 159 
last data collection from the general practitioner (GP) or at the next prescription for 160 
clarithromycin either alone or as part of HPT. 161 
 162 
A Poisson regression model was used to measure the rate ratio of outcome occurrence 163 
for those exposed to CHPT compared with clarithromycin free HPT. To control for 164 
confounding, a propensity score was developed as detailed in S2 Appendix. This was 165 
included as a covariate in the final outcome model. For the variables smoking status, 166 
alcohol status and Body Mass Index (BMI), there were some missing data and this 167 
was analysed by creating an unknown category. A sensitivity analysis using just 168 
complete records was carried out. The distribution of propensity scores for both 169 
groups was examined. (S3 Appendix) All patients whose scores fell outside of the 170 
overlapping region of both distributions were removed from the outcome model. In 171 
addition the top and bottom 5% of each distribution was removed from the outcome 172 
model. These adjustments were made because people treated contrary to extreme 173 
scores may have important unmeasured characteristics that could bias effect 174 
estimates[6]. We conducted a sensitivity analysis without trimming the 5% tails of 175 
each distribution to investigate the effect of this analysis decision.  176 
 177 
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A secondary analysis was performed where the study period was stratified by time 178 
since exposure into time windows. These strata were day 1-90, day 91-365, day 366-179 
730 (year 1-2) and day 731-1095 (year 2-3) post exposure. This analysis was designed 180 
to model any change in risk over time. There was insufficient power to look at shorter 181 
initial risk periods. 182 
Self-Controlled Case Series Study (SCCS) 183 
This study design is derived from rate modeling using a Poisson distribution and is 184 
analogous to cohort methodology. It relies on within person comparisons in a 185 
population with both the cardiovascular event outcome and exposure to CHPT.[7] [8] 186 
Incidence rate ratios are derived, comparing the rate of cardiovascular events during 187 
predefined risk periods following exposure to CHPT with that during all other 188 
observed periods. In this case the risk period was defined as the first year following 189 
exposure in this analysis. A major advantage of this design is that it removes the 190 
potential confounding effect of both recorded and unrecorded time invariant 191 
characteristics between people. Age, which varies over time, was adjusted for in the 192 
analysis (age bands are detailed in S4 Appendix). The method relies on several 193 
assumptions. These assumptions and our approach to handling them are detailed in S5 194 
Appendix. 195 
 196 
For this analysis, follow up was from a year following registration with the database 197 
until the patient died, moved to a different General Practice or the last data collection 198 
by the practice before January 2014. As with the cohort design, a secondary analysis 199 
was undertaken where several risk windows post-exposure were compared with the 200 
baseline rate: day 1-30, day 31-90, day 91-365, day 366-730 (year 1-2) and day 731-201 
1095 (year 2-3) post exposure. 202 
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 203 
Finally we employed a non-parametric SCCS design using cubic splines that does not 204 
require a pre-specified risk period to model the association between CHPT and first 205 
MI. This method allows better visualisation of the profile of relative risk over time[9]. 206 
Case-Time-Control Study (CTC) 207 
This design, described by Suissa[10], is a variation of the case-crossover study that 208 
controls for possible changes in exposure trends over time. The comparison is 209 
between a case period and a reference period within the same patient and the control 210 
patients are used to remove any bias from underlying prescription trends. Controls 211 
were matched on sex, age to the nearest year, general practice and registration period 212 
 213 
A conditional logistic regression model including the interaction between the 214 
case/control indicator and the time period indicator variables was performed. In this 215 
model, the effect of the exposure is given by the interaction term whereas the effect of 216 
the time period in the absence of exposure is given by the time period term. 217 
Data Analysis and Power considerations 218 
All analyses were conducted using Stata software, version 13 (StataCorp, College 219 
Station, TX). Prior to undertaking the analyses we estimated that we would have over 220 
99% power to detect a relative risk of 1.5 and 80% power to detect a relative risk of 221 
1.3 for the cohort analysis assuming the one year risk of MI is 4/1000 in adults 222 
(Coronary Heart Disease Statistics 2010, BHF). 223 
Ethics 224 
Ethical approval was granted by the London School of Hygiene and Tropical 225 
Medicine Ethics Committee (PR/203/203) and scientific approval was granted by the 226 
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Independent Scientific Advisory Committee of the Medicines and Healthcare 227 
Products Regulatory Agency (ISAC Reference 14_066R). 228 
Results 229 
Cohort Study 230 
We identified 37,530 patients in the database with at least one prescription of HPT. 231 
Figure 1 is a flow diagram of patients excluded from the cohort. 28,552 patients were 232 
included in the analysis. Of these 26,029 (91%) received CHPT and 2,523 (9%) 233 
received NHPT. For both groups the mean age at exposure was 53 years and the 234 
median follow up was 3 years. For the CHPT group the mean age at first MI was 67 235 
years compared to 69 years for the NHPT group. Table 1 shows the baseline 236 
characteristics for these groups (S6 Appendix shows the baseline characteristics for 237 
the cohort before the exclusions listed above). There were no large differences 238 
between the two groups on any characteristic. 239 
 240 
Table 2 shows the results of Poisson regression analysis. For first MI, the rate ratio for 241 
CHPT compared with NHPT exposure was 0.75 (95% CI: 0.45 to 1.24, p=0.26) after 242 
propensity score adjustment. There was no association. 243 
 244 
 245 
For first arrhythmia the adjusted rate ratio was 0.37 (95%CI: 0.22 to 0.63, p=0.001).  246 
For first stroke the adjusted rate ratio was 0.47 (95%CI: 0.26 to 0.84, p=0.01). There 247 
was good evidence that CHPT was associated with a reduced incidence of both first 248 
arrhythmia and first stroke. For all-cause mortality and cardiovascular mortality there 249 
was no evidence of an association in any of the analyses (see Table 2). 250 
 251 
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S7 Appendix shows the results for all outcomes stratified by time. There was some 252 
evidence for a protective association for first arrhythmia between years 1 and 2 post 253 
exposure. 254 
Self-Controlled Case Series Study 255 
962 patients were both exposed to CHPT and had a first MI within the registration 256 
period in CPRD. They had a mean follow up time of 14 years. The age adjusted rate 257 
ratio for incident first MI in the year after exposure to CHPT compared with the rest 258 
of follow up was 1.07 (95%CI: 0.85 to 1.34, p=0.58). There was no association 259 
between CHPT and first MI in the first year after taking it. In the secondary analysis 260 
comparing multiple risk windows over the 3 years following exposure to baseline 261 
there was some evidence of an increased risk year one to two post exposure with a 262 
rate ratio of 1.27 (95% CI: 1.01 to 1.61, p=0.04). These results are show in Table 3. A 263 
non-parametric SCCS analysis showed no association between exposure to CHPT and 264 
first MI and this is shown in Figure 2. As the risk windows 1-30d post exposure and 265 
31-90d post exposure contained very few events these were combined post hoc to 266 
improve power. The incidence rate ratio for days 1-90 post exposure was 1.43 (95% 267 
CI: 0.99 to 2.09 p=0.057), suggesting a possible association between exposure to 268 
CHPT and subsequent MI within 90 days. 269 
 270 
552 patients were both exposed to CHPT and had a first arrhythmia within the 271 
registration period in CPRD. They had a mean follow up time of 15 years. The age 272 
adjusted rate ratio for incident first arrhythmia in the year after exposure to CHPT 273 
compared with the rest of follow up was 1.24 (95%CI: 0.92 to 1.68, p=0.16). There 274 
was no association between CHPT and first arrhythmia in the first year after taking it. 275 
In the secondary analysis comparing multiple risk windows over the 3 years following 276 
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exposure to baseline there was evidence of an increased risk from day 30-90 post 277 
exposure with a rate ratio of 2.04 (1.19 to 3.51, p=0.01). There was no evidence of an 278 
increased risk during other time windows examined. 279 
 280 
S8 Appendix shows the SCCS analysis for first stroke. There was no evidence of an 281 
association between CHPT and increased risk of stroke. 282 
Case-Time-Control Study 283 
82,708 patients had a first MI during the registration period. These were matched to 284 
controls aiming for 4:1 matching. 7,797 patients did not have a suitable match and 285 
were excluded from the analysis. 142 patients were excluded because they did not 286 
have three years of follow up before first MI. The remaining 74,769 cases were 287 
matched to 258,696 controls. 288 
 289 
The odds ratio for exposure to CHPT in the year before first MI compared with the 290 
reference period between one and two years before MI was 0.86 (95% CI: 0.59 to 291 
1.26, p=0.44). There was no association between exposure to CHPT and first MI 292 
within a year. We carried out a post hoc analysis comparing the current period 0-90 293 
days before first MI with a reference period 91-180 days before first MI to mirror the 294 
post hoc SCCS analysis described above. The odds ratio comparing these periods was 295 
1.32 (95% CI: 0.62 to 2.80, p=0.74).  296 
 297 
There was no association between exposure to CHPT and either first arrhythmia or 298 
first stroke. Table 4 shows the results of the CTC analysis for all outcomes. 299 
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Sensitivity Analyses 300 
359 CPRD patients with linked HES records were exposed to clarithromycin 301 
containing HPT and had a first MI event within follow up. An SCCS analysis on this 302 
cohort using event dates recorded in HES showed an age adjusted rate ratio for 303 
incident first MI in the thirty days after exposure to CHPT compared with the rest of 304 
follow up of 3.77 (95%CI: 1.85 to 7.68, p<0.001). There was no association with any 305 
other time periods. The results are shown in S9 Appendix. 306 
This sensitivity analysis was not conducted for the first arrhythmia outcome because 307 
the databases were often discordant with respect to the first arrhythmia event. In 308 
particular, many first arrhythmias were coded in CPRD but not in HES which 309 
probably reflects the fact that many of these cases did not require inpatient admission. 310 
These discordant events might possibly reflect historical events coded more recently  311 
 312 
None of the other sensitivity analyses conducted conflicted with our main analyses. 313 
Results not shown. 314 
Discussion 315 
This study found no evidence that clarithromycin in the context of HPT was 316 
associated with the first MI within a year of exposure. There was, however, some 317 
evidence of a short lived increased risk of first MI and first arrhythmia within 90 days 318 
of exposure in the SCCS. The statistical evidence for this result was weak and it 319 
should be treated with caution. In particular, arrhythmia events were discordant when 320 
compared to hospital data and although this is likely to represent milder arrhythmias 321 
that did not require hospital admission the possibility remains that there was increased 322 
case finding by clinicians aware of recent clarithromycin use and the potential 323 
association with arrhythmia.  324 
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Despite these caveats, it is consistent with the summary of product characteristics 325 
document for clarithromycin, which lists prolonged QT interval as a recognised side 326 
effect. Prolonged QT interval is a cause of arrhythmia and arrhythmia in turn can 327 
precipitate MI. 328 
 329 
The sensitivity analysis of patients with linked HES records with more accurate HES 330 
outcome dates revealed a strong short term effect within 30 days of exposure. This 331 
suggests that there is some temporal lag in CPRD event recording and the true risk 332 
period might be much shorter. 333 
 334 
The cohort analysis suggested a protective effect of CHPT on the incidence of first 335 
stroke and first arrhythmia. However this finding would not be predicted by the 336 
known pharmacology of clarithromycin. Moreover it was not confirmed by the SCCS 337 
or CTC analyses and should be viewed with caution. Clinicians will be aware of the 338 
association between clarithromycin and prolonged QT interval. It is possible that 339 
patients at high risk of ventricular arrhythmia, for example with a relevant family 340 
history, would be prescribed NHPT preferentially and this would manifest as a 341 
protective effect in a cohort analysis comparing patients prescribed CHPT with 342 
patients prescribed clarithromycin free HPT. This may not be captured by the 343 
propensity score for two reasons. Firstly, there is likely to be significant under-344 
reporting of risk factors for arrhythmia such as family history of ventricular 345 
arrhythmia in the CPRD; there were less than five patients in the cohort with a code 346 
for this. Secondly, the propensity score adjusted for history of any arrhythmia. This 347 
includes all subtypes and is dominated by atrial fibrillation. This is an imperfect 348 
covariate, however as there were only ten patients in the cohort with codes for 349 
17 
 
ventricular arrhythmia or long QT syndrome, including a more specific covariate was 350 
not feasible in this study. Since arrhythmia is a cause of stroke this could also be a 351 
cause of the protective effect seen for stroke also. Comparing the discordant results of 352 
the cohort and the self-controlled methods we feel that it is more plausible that the 353 
cohort suffers from residual uncontrolled confounding than the alternative explanation 354 
that clarithromycin is protective for arrhythmia and stroke and that the self-controlled 355 
designs were biased towards the null.  356 
Comparison between study designs 357 
All three methods were consistent in not finding any long term harmful association 358 
between CHPT and any of the study outcomes. 359 
 360 
The SCCS analysis showed some evidence of short term risk of MI and arrhythmia 361 
that was not demonstrated in the cohort analysis. However, the cohort analysis lacked 362 
power as evidenced by very wide confidence intervals which were unable to rule out 363 
potentially large effects. A post hoc CTC analysis of the short term risk period for MI 364 
suggested an effect estimate consistent with the SCCS but with confidence intervals 365 
crossing unity.  366 
Strengths and weaknesses 367 
The strengths of this study are that it draws from a large representative primary care 368 
population and therefore is generalizable to the UK population; the exposure is 369 
restricted to an indication which is unlikely to be biased by acute infection and it 370 
employs several analytic methods with different susceptibilities to bias to answer the 371 
same question which reduces the risk that congruent findings across methods are due 372 
to bias. 373 
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 374 
A weakness of the cohort analysis was that the NHPT group was much smaller that 375 
the CHPT group. This compromised the power of this analysis. NHPT regimes all 376 
contain metronidazole. It is likely that these are less often prescribed because 377 
metronidazole is more likely to cause gastrointestinal side effects such as nausea and 378 
vomiting. Additionally, the BNF recommends these regimes as second line and so 379 
they are likely to be prescribed only for patients with allergy to HPT regimes 380 
containing clarithromycin. We do not know of any reason why this prescribing 381 
behaviour would result in differences in baseline cardiovascular risk between groups 382 
and the baseline characteristics measures were similar (Table 1). The consistency with 383 
the two self-controlled analyses suggests that any bias from this is unlikely to have 384 
significantly affected the analysis. 385 
 386 
The CTC analysis compared the first MI in the year following exposure to a baseline 387 
period between one and two years following exposure. This would be sensitive to a 388 
risk within the year following exposure but would underestimate a longer term risk as 389 
this would make the exposure period more similar to the baseline period.  390 
 391 
The SCCS analysis can be biased if the outcome event causes significant censoring of 392 
subsequent exposures. This can occur with events that are associated with subsequent 393 
death. Although there is an increased mortality following first MI this represented a 394 
small proportion of the cohort (less than 10% died in the year after first MI). Previous 395 
studies have shown that the increased mortality following first MI is not sufficient to 396 
cause significant bias [11,12]. We performed a sensitivity analysis excluding patients 397 
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who died in the first 30 days following first MI and found no difference in the study 398 
estimates. 399 
 400 
This study was restricted to clarithromycin given as part of HPT. While this 401 
restriction was employed to reduce confounding by acute infection, the results are 402 
only strictly applicable to this particular indication. However, there is no good reason 403 
to suppose that adverse effects of taking clarithromycin would differ by indication. 404 
 405 
For the outcome of first arrhythmia, there is already evidence that clarithromycin 406 
prolongs the QT interval and this would be expected to cause certain arrhythmia 407 
subtypes. In this study we do not have sufficiently detailed data on arrhythmia 408 
subtype to confirm whether the short term association we reported was entirely due to 409 
this potentially causal mechanism. If this were the only underlying causal mechanism, 410 
our broad outcome definition of all first arrhythmias would be expected to 411 
underestimate the strength of this causal association with specific arrhythmia subtypes 412 
such as torsades de pointes. 413 
 414 
The outcomes measured in this study were first occurrence of the respective 415 
cardiovascular event. Therefore, the findings of this study are only strictly applicable 416 
to patients with no history of that particular cardiovascular event. However, other well 417 
established cardiovascular risk factors, such as hypertension and smoking, carry the 418 
same relative risk regardless of a patient’s past medical history. Therefore, there are 419 
no grounds to suspect a different effect from exposure to clarithromycin for patients 420 
with a cardiovascular event history compared with those who have no such history.  421 
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Comparison with previous studies 422 
Jespersen et al. conducted an RCT investigating the possible benefit of clarithromycin 423 
in secondary prevention of MI[1]. None of the primary or secondary outcomes of the 424 
study showed any effect. However they reported an increased risk of both 425 
cardiovascular mortality and a tertiary composite outcome (including cardiovascular 426 
mortality, MI, stroke, unstable angina and peripheral vascular disease). This 427 
association could therefore be vulnerable to multiple testing.  428 
 429 
Schembri et al. reported two cohorts comparing clarithromycin with other antibiotics 430 
to treat pneumonia and infective chronic obstructive pulmonary disease exacerbations 431 
respectively[2]. It is possible that this study was susceptible to indication bias where 432 
frailer patients could have been preferentially given clarithromycin over comparator 433 
antibiotics such as amoxicillin and this frailty might not have been adequately 434 
captured by the measured covariates.  435 
 436 
Svanstrom et al. performed a propensity score adjusted cohort analyses comparing the 437 
risk of cardiac death after exposure to clarithromycin with exposure to penicillin 438 
V[13]. They found an increased risk of cardiac death during current use (adjusted rate 439 
ratio 1.76, 95% CI: 1.08 to 2.85) that did not persist in the 30 days following the end 440 
of treatment. They repeated the analysis substituting roxithromycin for clarithromycin 441 
and did not find any association (adjusted rate ratio 1.04, 95% CI: 0.72 to 1.51). They 442 
concluded that clarithromycin was associated with an acute cardiac risk that did not 443 
persist after treatment was stopped. In this study there were clear baseline differences 444 
between the clarithromycin group and the penicillin V control group, the latter being 445 
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younger, on less medication and having less respiratory illness. Therefore, the acute 446 
risk could have been related to these baseline differences.  447 
 448 
Finally, we looked at this association in a Hong Kong population employing a similar 449 
protocol[3]. Due to the smaller size of the Hong Kong database the cohort method 450 
could not be applied to Helicobacter pylori treatment only. Instead, the self-controlled 451 
methods were applied to a Helicobacter pylori treatment cohort and a propensity score 452 
controlled cohort method was used to compare clarithromycin to amoxicillin for any 453 
indication. This study showed increased risk of MI during current use of 454 
clarithromycin in all study designs but no long term risk after finishing the course. As 455 
with the study by Schembri et at. [2] discussed above, the cohort method is 456 
susceptible to indication bias. However, the congruence with self-controlled methods 457 
makes this less likely here. 458 
 459 
Our cohort was slightly younger than the first two papers (mean 53y compared with 460 
65 and 72 years respectively) and comparable to the latter two. The spread of ages in 461 
our study were appreciably wider (SD 16y compared with 10.3y in Jespersen et al. 462 
and 9.6y in Svanstrom et al.). This suggests that our study encompasses a broader 463 
cross-section of the population than the previous studies. 464 
 465 
The study we report does not confirm the long term risk of clarithromycin suggested 466 
by Jespersen et al. and Schembri et al. However, we cannot rule out a short term 467 
increased risk of MI and arrhythmia, which is consistent with Svanstrom et al. and 468 
Wong et al. 469 
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Clinical implications 470 
Clarithromycin is widely used in UK primary care for a range of indications. The 471 
suggestion of a raised long term cardiovascular risk was therefore a major concern. 472 
This study does not support this long term association. The SCCS analysis was 473 
compatible with a short term risk of both MI and arrhythmia, as expected, given the 474 
known pharmacology of clarithromycin. The SCCS method cannot directly provide 475 
absolute estimates of risk, however, if the risk of MI in the cohort group taking NHPT 476 
is used as a baseline comparator, this analysis would be compatible with an absolute 477 
rate increase for MI of 3 events per 10,000 treatment courses (assuming a maximum 478 
risk period of 90 days per course). For first arrhythmia the absolute rate increase 479 
would be 8 events per 10,000 treatment courses. At present, the Summary of Product 480 
Characteristics for clarithromycin advises caution when prescribing clarithromycin in 481 
patients with coronary heart disease and recommends not prescribing clarithromycin 482 
to patients with a history of ventricular arrhythmia. 483 
Conclusions 484 
This study found no long term association between clarithromycin prescribed as part 485 
of HPT and cardiovascular events in a large UK primary care cohort. Our results are 486 
consistent with a short-term increased risk of MI and arrhythmia within 90 days of 487 
exposure.  488 
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Tables 525 
 526 
Table 1: Baseline characteristics for patients included in the cohort study between 1991 and 2013 with a 527 
median follow up of 3 years 528 
Characteristic 
Clarithromycin containing HPT 
regime 
Clarithromycin-free HPT 
regime 
 N (%) N (%) 
Sex     
Male 12386 (47.6%) 1196 (47.4%) 
Female 13643 (52.4%) 1327 (52.6%) 
Age     
0-40y 6114 (23.5%) 592 (23.5%) 
40-50y 5365 (20.6%) 518 (20.5%) 
50-60y 5343 (20.5%) 529 (21.0%) 
60-70y 4976 (19.1%) 478 (19.0%) 
70-80y 3135 (12.0%) 301 (11.9%) 
>80y 1096 (4.2%) 105 (4.2%) 
Smoking status     
non-smoker 10392 (39.9%) 1052 (41.7%) 
current smoker 7409 (28.5%) 632 (25.1%) 
ex-smoker 7884 (30.3%) 812 (32.2%) 
unknown 344 (1.3%) 27 (1.1%) 
Alcohol status     
non-drinker 4330 (16.6%) 442 (17.5%) 
ex-drinker 1133 (4.4%) 120 (4.8%) 
current drinker (unknown quantity) 102 (0.4%) 11 (0.4%) 
<2u/day 4387 (16.9%) 447 (17.7%) 
3-6u/day 10900 (41.9%) 1016 (40.3%) 
>6u/day 2588 (9.9%) 234 (9.3%) 
unknown 2589 (10.0%) 253 (10.0%) 
Body Mass Index     
normal (18.5-25) 9642 (37.0%) 941 (37.3%) 
overweight (25-30) 8884 (34.1%) 856 (33.9%) 
obese I (30-35) 3585 (13.8%) 367 (14.6%) 
obese II (35-40) 1109 (4.3%) 115 (4.6%) 
obese III (>40) 472 (1.8%) 44 (1.7%) 
unknown 2337 (9.0%) 200 (7.9%) 
Consulted GP in year before exposure 25948 (99.7%) 2514 (99.6%) 
History of cardiovascular disease 4226 (16.2%) 366 (14.5%) 
History of heart failure 755 (2.9%) 59 (2.3%) 
History of arrhythmia 1434 (5.5%) 127 (5.0%) 
History of hypertension 8240 (31.7%) 783 (31.0%) 
History of COPD 1682 (6.5%) 167 (6.6%) 
History of asthma 3615 (13.9%) 350 (13.9%) 
History of hyperlipidaemia 4605 (17.7%) 416 (16.5%) 
History of diabetes mellitus 3734 (14.4%) 342 (13.6%) 
25 
 
History of cancer 4884 (18.8%) 461 (18.3%) 
History of NSAID use 1942 (7.5%) 167 (6.6%) 
History of oral corticosteroid use 383 (1.5%) 36 (1.4%) 
History of antipsychotic use 854 (3.3%) 81 (3.2%) 
History of antidepressant use 3101 (11.9%) 294 (11.7%) 
History of lipid lowering drug use 2948 (11.3%) 336 (13.3%) 
History of anticoagulant use 226 (0.9%) 32 (1.3%) 
History of antiplatelet use 2156 (8.3%) 242 (9.6%) 
History of nitrate use 649 (2.5%) 56 (2.2%) 
History of digoxin use 146 (0.6%) 15 (0.6%) 
History of antiarrhythmic drug use 59 (0.2%) 6 (0.2%) 
History of beta blocker use 2192 (8.4%) 230 (9.1%) 
History of thiazide diuretic use 1892 (7.3%) 181 (7.2%) 
History of calcium channel blocker use 2072 (8.0%) 216 (8.6%) 
History of ACEI/ARB use 2843 (10.9%) 316 (12.5%) 
History of loop diuretic use 718 (2.8%) 62 (2.5%) 
     
Total 26029  2523  
ACEI = Angiotensin Converting Enzyme Inhibitor, ARB = Angiotensin Receptor Blocker, COPD = Chronic Obstructive 
Pulmonary Disease, HPT = Helicobacter pylori Treatment, NSAID = Non-Steroidal Anti-Inflammatory Drug 
 529 
  530 
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Table 2: Results of the propensity score adjusted cohort analysis using Poisson regression. 531 
 
Patients 
(N) 
Patient-
years 
Event
s 
(N) 
Crude IRR 
(95% CI) 
PS Adjusted IRR 
(95% CI) 
First MI 
         
CHPT 26029 62118.9
8 
174 0.89  (0.54-
1.44) 
p=0.62 0.75  (0.45-
1.24) 
p=0.26 
NHPT 2523 5688.98 18 1.00 
     
First Stroke 
         
CHPT 26686 63847.3
6 
68 0.38  (0.22-
0.66) 
p=0.001 0.47  (0.26-
0.84) 
p=0.01 
NHPT 2540 5746.98 16 1.00 
     
First 
Arrhythmia 
         
CHPT 26586 63581.6
7 
95 0.43  (0.26-
0.69) 
p=0.001 0.37  (0.22-
0.63) 
p=0.001 
NHPT 2527 5702.77 20 1.00 
     
All cause 
mortality 
         
CHPT 26827 64235.6
9 
2621 1.09  (0.95-
1.25) 
p=0.22 0.97  (0.84-
1.12) 
p=0.66 
NHPT 2582 5851.81 219 1.00 
     
Cardiovascular 
mortality 
         
CHPT 11616 27729.7
1 
416 1.05  (0.73-
1.50) 
p=0.80 0.93  (0.64-
1.34) 
p=0.69 
NHPT 1058 2234.28 32 1.00   1.00   
IRR = Incidence rate ratio, CI = confidence interval, HPT = Helicobacter pylori treatment MI = myocardial infarction CHPT = 532 
Helicobacter pylori treatments containing clarithromycin, NHPT = clarithromycin free Helicobacter pylori treatment 533 
 534 
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Table 3: Results of the self-controlled case series analysis for the outcomes of first MI and first arrhythmia. 536 
 
Patients 
(N) Patient-years 
Events 
(N) 
Age adjusted IRR 
(95% CI)  
Primary Outcome: First MI 
(median follow up 14.0y)       
Single risk window       
Baseline 962 12718 876 1   
1 year post-exposure 961 932.5 84 1.07 (0.85-1.34) p=0.58 
Multiple Risk window       
Baseline 962 11104 731 1   
day 1-30 post-exposure 961 81.08 9 1.32 (0.68-2.55) p=0.41 
day 31-90 post-exposure 954 159.42 20 1.50 (0.96-2.35) p=0.08 
day 91-365 post exposure 941 694.45 55 0.97 (0.74-1.29) p=0.84 
year 1-2 post-exposure 886 843.08 85 1.27 (1.01-1.61) p=0.04 
year 2-3 post-exposure 800 768.74 60 1.01 (0.77-1.33) p=0.92 
       
       
Secondary Outcome: First Arrhythmia 
(median follow up 15.0y)       
Single risk window       
Baseline 552 7727.83 498 1   
1 year post-exposure 552 542.11 50 1.24 (0.92-1.68) p=0.16 
Multiple Risk window       
Baseline 551 6761.63 432 1   
day 1-30 post-exposure 552 46.57 5 1.42 (0.58-3.44) p=0.44 
day 31-90 post-exposure 548 91.83 14 2.04 (1.19-3.51) p=0.01 
day 91-365 post exposure 543 405.14 31 0.99 (0.68-1.45) p=0.97 
year 1-2 post-exposure 514 500.77 35 0.89 (0.63-1.27) p=0.53 
year 2-3 post-exposure 473 464 31 0.83 (0.57-1.2) p=0.33 
All IRRs are age adjusted and derived from conditional Poisson regression. MI = myocardial infarction, CI = confidence 537 
interval, IRR = incidence rate ratio 538 
 539 
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Table 4: Results of case-time-control analysis for all outcomes. 541 
 
Patients 
(N) 
Patient-years Events 
(N) 
OR 
(95% CI) 
First MI:       
Exposure Effect 33465 737176 74769 0.86 (0.59-1.26) p=0.44 
Period Effect    1.08 (0.9-1.31) p=0.41 
Case-crossover Equivalent    0.93 (0.67-1.29) p=0.68 
       
First Stroke: 
      
Exposure Effect 53430 108812 11025 1.17 (0.58-2.36) p=0.67 
Period Effect 
   
1.10 (0.67-1.82) p=0.7 
Case-crossover Equivalent 
   
1.29 (0.78-2.11) p=0.32 
       
First Arrhythmia: 
      
Exposure Effect 87256 179566 18137 1.46 (0.79-2.7) p=0.23 
Period Effect 
   
0.96 (0.64-1.43) p=0.84 
Case-crossover Equivalent 
   
1.40 (0.88-2.24) p=0.16 
Conditional Logistic Regression Analysis. Exposure effect = OR for the effect of exposure after adjusting for  542 
differences in prescription patterns between the two periods. Period effect = OR for period indicator variable:  543 
this represents the effect of the difference in prescription rates between the two periods that is not due to  544 
exposure effects.  Case-crossover equivalent = crude OR for exposure period compared with reference period:  545 
this represents the total effect comparing periods before adjusting for differences between periods due to  546 
underlying prescription patterns i.e. a simple case-crossover analysis. OR = Odds Ratio, MI = myocardial  547 
infarction, CI = confidence interval. 548 
 549 
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Figure Legends 551 
 552 
Figure 1: Flow chart for the propensity score adjusted cohort analysis of first MI 553 
 554 
Figure 2: Non-parametric self-controlled case series analysis of the relative incidence 555 
of first myocardial infarction after exposure to clarithromycin containing Helicobacter 556 
pylori Therapy. 557 
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